Compare · NVO vs RAPP
NVO vs RAPP
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rapport Therapeutics Inc. (RAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RAPP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $217.28B, about 109.6x RAPP ($1.98B).
- Over the past year, NVO is down 27.0% and RAPP is up 188.0% - RAPP leads by 215.0 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 11 for RAPP).
- Company
- Novo Nordisk A/S
- Rapport Therapeutics Inc.
- Price
- $49.08-0.41%
- $41.36+1.82%
- Market cap
- $217.28B
- $1.98B
- 1M return
- +11.62%
- +18.00%
- 1Y return
- -27.00%
- +188.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RAPP
- Chief Operating Officer Gault Cheryl sold $415,798 worth of shares (10,000 units at $41.58) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 149,914 units (SEC Form 4)
- Chief Executive Officer Ceesay Abraham sold $327,398 worth of shares (8,220 units at $39.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 548,027 units (SEC Form 4)
- SEC Form 144 filed by Rapport Therapeutics Inc.
- SEC Form 144 filed by Rapport Therapeutics Inc.
- Leerink Partners initiated coverage on Rapport Therapeutics with a new price target
- SEC Form 4 filed by Director Maraganore John
- SEC Form 4 filed by Director Perez Robert J
- SEC Form 4 filed by Director Paul Steven M
- SEC Form 4 filed by Director Silva Paul M
- SEC Form 4 filed by Director Healy James